http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Collateral status affects the onset-to-reperfusion time window for good outcome
Kim, Byung Moon,Baek, Jang-Hyun,Heo, Ji Hoe,Nam, Hyo Suk,Kim, Young Dae,Yoo, Joonsang,Kim, Dong Joon,Jeon, Pyoung,Baik, Seung Kug,Suh, Sang Hyun,Lee, Kyung Yol,Kwak, Hyo Sung,Roh, Hong Gee,Lee, Young- British Medical Association 2018 Journal of neurology, neurosurgery and psychiatry Vol.89 No.9
<P>Conclusions Earlier successful recanalisation was strongly associated with good outcome in poor collateral group; however, this association was weak during the tested time window in good collateral group. This suggests that the ORT window for good outcome can be adjusted according to collateral status.</P>
Kim, Suk Jung,Roh, Hong Gee,Jeon, Pyoung,Kim, Keon Ha,Lee, Kwang Ho,Byun, Hong Sik,Moon, Won-Jin,Kim, Gyeong-Moon,Kim, Young-Wook,Kim, Dong Ik The Korean Radiological Society 2007 KOREAN JOURNAL OF RADIOLOGY Vol.8 No.4
<P><B>Objective</B></P><P>The aim of this study was to examine the incidence of ischemia during protected carotid artery stenting (CAS) as well as to compare the protective efficacy of the balloon and filter devices on diffusion-weighted MR imaging (DWI).</P><P><B>Materials and Methods</B></P><P>Seventy-one consecutive protected CAS procedures in 70 patients with a severe (> 70%) or symptomatic moderate (> 50%) carotid artery stenosis were examined. A balloon device (PercuSurge GuardWire) and a filter device (FilterWire EX/EZ, Emboshield) was used in 33 cases (CAS-B group) and 38 cases (CAS-F group) to prevent distal embolization, respectively. All the patients underwent DWI within seven days before and after the procedures. The number of new cerebral ischemic lesions on the post-procedural DWI were counted and divided into ipsilateral and contralateral lesions according to the relationship with the stenting side.</P><P><B>Results</B></P><P>New cerebral ischemic lesions were detected in 13 (39.4%) out of the 33 CAS-Bs and in 15 (39.5%) out of the 38 CAS-Fs. The mean number of total, ipsilateral and contralateral new cerebral ischemic lesion was 2.39, 1.67 and 0.73 in the CAS-B group and 2.11, 1.32 and 0.79 in the CAS-F group, respectively. No statistical differences were found between the two groups (<I>p</I> = 0.96, 0.74 and 0.65, respectively). The embolic complications encountered included two retinal infarctions and one hemiparesis in the CAS-B group (9.09%), and one retinal infarction, one hemiparesis and one ataxia in the CAS-F group (7.89%). There was a similar incidence of embolic complications in the two groups (<I>p</I> = 1.00).</P><P><B>Conclusion</B></P><P>The type of distal protection device used such as a balloon and filter does not affect the incidence of cerebral embolization after protected CAS.</P>
Sung, Changmin,Jung, Eunok,Choi, Kwon-Young,Bae, Jin-hyung,Kim, Minsuk,Kim, Joonwon,Kim, Eun-Jung,Kim, Pyoung Il,Kim, Byung-Gee Springer-Verlag 2015 Applied microbiology and biotechnology Vol.99 No.16
<P>Hydroxylated fatty acids (HFAs) are used as important precursors for bulk and fine chemicals in the chemical industry. Here, to overproduce long-chain (C16-C18) fatty acids and hydroxy fatty acid, their biosynthetic pathways including thioesterase (Lreu_0335) from Lactobacillus reuteri DSM20016, beta-hydroxyacyl-ACP dehydratase (fabZ) from Escherichia coli, and a P450 system (i.e., CYP153A from Marinobacter aquaeolei VT8 and camA/camB from Pseudomonas putida ATCC17453) were overexpressed. Acyl-CoA synthase (fadD) involved in fatty acid degradation by beta-oxidation was also deleted in E. coli BW25113. The engineered E. coli FFA4 strain without the P450 system could produce 503.0 mg/l of palmitic (C-16) and 508.4 mg/l of stearic (C-18) acids, of which the amounts are ca. 1.6- and 2.3-fold higher than those of the wild type. On the other hand, the E. coli HFA4 strain including the P450 system for omega-hydroxylation could produce 211.7 mg/l of omega-hydroxy palmitic acid, which was 42.1 +/- 0.1 % of the generated palmitic acid, indicating that the hydroxylation reaction was the rate-determining step for the HFA production. For the maximum production of omega-hydroxy palmitic acid, NADH, i.e., an essential cofactor for P450 reaction, was overproduced by the integration of NAD(+)-dependent formate dehydrogenase (FDH) from Candida boidinii into E. coli chromosome and the deletion of alcohol dehydrogenase (ADH). Finally, the NADH-level-optimized E. coli strain produced 610 mg/l of omega-hydroxy palmitic acid (omega-HPA), which was almost a threefold increase in its yield compared to the same strain without NADH overproduction.</P>
Park, Hae-Min,Kim, Byung-Gee,Chang, Dongsook,Malla, Sailesh,Joo, Hwang-Soo,Kim, Eun-jung,Park, Sei-Jin,Sohng, Jae Kyung,Kim, Pyoung Il Springer-Verlag 2013 Applied microbiology and biotechnology Vol.97 No.3
<P>Identification of secondary metabolites produced by cryptic gene in bacteria may be difficult, but in the case of nonribosomal peptide (NRP)-type secondary metabolites, this study can be facilitated by bioinformatic analysis of the biosynthetic gene cluster and tandem mass spectrometry analysis. To illustrate this concept, we used mass spectrometry-guided bioinformatic analysis of genomic sequences to identify an NRP-type secondary metabolite from Streptomyces peucetius ATCC 27952. Five putative NRPS biosynthetic gene clusters were identified in the S. peucetius genome by DNA sequence analysis. Of these, the sp970 gene cluster encoded a complete NRPS domain structure, viz., C-A-T-C-A-T-E-C-A-T-C-A-T-C domains. Tandem mass spectrometry revealed that the functional siderophore peptide produced by this cluster had a molecular weight of 644.4?Da. Further analysis demonstrated that the siderophore peptide has a cyclic structure and an amino acid composition of AchfOrn-Arg-hOrn-hfOrn. The discovery of functional cryptic genes by analysis of the secretome, especially of NRP-type secondary metabolites, using mass spectrometry together with genome mining may contribute significantly to the development of pharmaceuticals such as hybrid antibiotics.</P>